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Abstract
Objectives: Scarcity of liver grafts has led to the use of
marginal donors, consequently increasing the number
of complications posttransplant. To prevent this
situation, several indicators have been developed.
However, important differences remain among
countries. Here, we compared an early-risk liver
transplant indicator based on the Spanish Liver
Transplant Registry, called the Graft Risk Index, versus
the US donor risk index and the Eurotransplant donor
risk index.
Materials and Methods: The new indicator was based
on prospectively collected data from 600 adult liver
transplants performed in our center. We considered 2
events to compare the indexes: graft survival and
rejection-free graft survival, with Cox proportional
regression for analyses. Power to predict graft survival
was evaluated by calculating the receiver operating
characteristic area under the curve.
Results: We found no differences between the US and
Eurotransplant donor risk indexes in prediction of
patients with and without early graft failure. With
regard to early survival, only the Graft Risk Index
allowed better survival discrimination, in which
survival progressively decreased with values ≥ 3 (with
probability of graft survival at 1 month of 68%; 95%
confidence interval, 46.2-82.5). This increase in risk was
significant compared with the standard group (hazard
ratio of 10.15; 95% confidence interval, C 3.91- 26.32;
P < .001). We calculated powers of prediction of 0.52
(95% confidence interval, 0.43-0.62), 0.54 (95%
confidence interval, 0.45-0.65), and 0.69 (95%
confidence interval, 0.61-0.77) for donor risk index,
Eurotransplant donor risk index, and early Graft Risk
Index, respectively.
Conclusions: Neither the US donor risk index nor the
Eurotransplant donor risk index was valid for our
Spanish liver donation and transplant program.
Therefore, an indicator to predict posttransplant graft
survival that is adapted to our environment is
necessary. This national Graft Risk Index can be a
useful tool to optimize donor-recipient matching.
Key words: Donor Risk Index, Early complications,
Eurotransplant Donor Risk index, Graft survival, Organ
Procurement and Transplantation Network, Rejection-free
graft survival
Introduction
In Spain, more than 1000 transplant procedures have
been performed each year in the past decade; more
than half of these patients will have at least 1
significant complication during their first year
posttransplant.1 Specifically, in the immediate
postoperative period, they are admitted to the
intensive care unit (ICU) and may have systemic
complications, including respiratory, cardiovascular,
renal, and hematologic, as well as graft complications
(technical and nontechnical), including primary graft
failure, arterial or portal thrombosis, and rejection.
These complications can lead to longer ICU and
hospital stays and can result, in many cases, in graft
failure (retransplant) or even patient death.
High complication rates may be associated with
the use of expanded criteria donors and/or recipients
with comorbidities and poor clinical conditions
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pretransplant. An important way to prevent 
these complications is appropriate donor-recipient
matching. For this purpose, several indicators have
been described: Model for End-Stage Liver Disease
(MELD), Child-Turcotte-Pugh score,2 Newly Derived
Discrimination Function,3 Score of Liver Donor,4
the Donor Risk Index (DRI),5 Survival Outcome
Following Liver Transplantation (SOFT),6 donor-
MELD (D-MELD),7 Balance of Risk score,8
Eurotransplant Donor Risk Index (ET-DRI),9 Neural
Network-Correct Classification Rate, Neural
Network-Minimum Sensitivity,10 Neural Network,11
and the Donor Liver Index.12
There are important differences among organ
donation and transplant programs in different
countries and organizations in terms of both donor
characteristics and transplant results. These
differences are more striking regarding donor age
and ethnicity, number of donors after brain death
versus donors after cardiac death, causes of brain
death, controlled hepatic bipartition, and other
factors. For example, for the French donation
program, Winter and associates have shown that DRI
and ET-DRI were not useful.13
All of the above factors indicate that donors and
recipients can differ between countries and/or
regions; therefore, a region-specific scoring system
that could be used for liver selection and allocation
would be appropriate. The Spanish Liver Transplant
Registry (RETH; for its acronym in Spanish) was
created with the cooperation of professional teams
incorporated in the Spanish Liver Transplantation
Society and the Spanish National Transplant
Organization. The RETH records the experiences of
liver transplant in Spain; the database contains
structured data of all liver transplants performed in
the country, thus serving as a knowledge repository
of our own experience.
In this study, our main objective was to determine
graft quality when we compared the DRI, the 
ET-DRI, and our region-specific Graft Risk 
Index (GRI).14 We used data from 22 846 liver
transplants from RETH, which included liver
transplant procedures done at our center. The GRI, a
new early risk indicator in liver transplant, was
based on outcomes recorded in RETH. This Spanish-
specific indicator, which combines donor- and
recipient-related factors, could facilitate patient-
specific decision-making in organ selection and
allocation.
Materials and Methods
The description of the new indicator was based on
data collected from the annual report from RETH,15
which describes donor characteristics and liver
transplant results in Spain. In particular, the structured
data include 22 846 liver transplants, which were
performed in 24 transplant centers from 1984 to 2016.
This report is in the public domain and is available
online.
For validation of described indicators, we
included prospectively collected data of 600 adult
liver transplants (recipients were older than 15 years)
performed consecutively in our center. The study
complied with Organic Law 15/1999 on Personal Data
Protection. It was also approved by the Aragon ethics
committee (CodeCEICA PI18/0097) on April 24, 2018.
The RETH report also included a Cox proportional
hazards regression analysis of the factors associated
with overall graft survival. Results are expressed as
Cox regression values with their 95% confidence
intervals (95% CI).
Based on the Cox regression equation itself, ln 
(λt) = a + b1x1 + b2x2 + … + bnxn, an indicator can be
defined as the exponential (inverse logarithm) of a
linear risk score. By grouping variables with
statistically significant differences for multivariate
analysis, 2 GRIs can be defined, one overall (global)
and one early (< 1 month).
To evaluate the indicators, 2 types of events were
considered. The first event was graft survival,
defined as the period from date of transplant to date
of retransplant or death for any reason, whichever
occurred first. The second event was rejection-free
graft survival, defined as the period from date of
transplant to date of retransplant or death due to
chronic graft dysfunction, whichever occurred first.
The Hosmer-Lemeshow goodness of fit test 
(P < .05) was used to evaluate model fit. We then
obtained the values used to generate the logistic
regression curve: regression coefficients (β0 and β1)
with their corresponding standard errors, the Wald
statistic, and odds ratio and confidence intervals.
To compare indicators, graft survival curves were
calculated by indicator-related risk group using
Kaplan-Meier estimations. The hazard ratio (HR) for
each risk group was estimated versus a standard
group using a Cox regression model.
The accuracy of DRI, ET-DRI, and GRI to predict
graft survival was assessed using the area under the
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curve in a receiver operating characteristic curve
analysis, where 1 represents perfect discrimination
and 0.5 represents discrimination not above chance
level.
A Wald P value < .05 was considered significant.
All analyses were performed with IBM SPSS
Statistics version 22.0 (IBM Corporation, Chicago, IL,
USA).
Results
To describe and calculate the GRI, global and early
GRIs were obtained using Cox logistic regression
analysis on global graft survival data from the RETH
(Table 1). Table 1 shows an example of a global GRI
with risk 1 and an example of maximum risk 
(GRI = 81.04); the examples shown are accompanied
by DRI and ET-DRI scores.
To validate new indicators besides DRI and 
ET-DRI, data from 600 adult liver transplants
performed at our center were included. Validation
series data are described in Tables 2, 3, and 4.
With reference to the logistic function of the GRI,
the Hosmer-Lemeshow test revealed that the
probabilities observed were similar to those expected
for the 3 indicators concerned: DRI (P = .20), ET-DRI
(P = .25), global GRI (P = .20), and early GRI (P = .28).
Figure 1 shows the logistic equation curve of the
early GRI, together with the values observed in the
early GRI intervals. An early GRI value of 1
corresponded to a probability of graft failure (5.07%),
and each point of early GRI increase indicated that
the probability of having a graft failure was
multiplied by 2.06 (95% CI, 1.57-2.96).
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table 1. Prospective Calculation of Global and Early Graft Risk Index: Formula and Examples Compared With US Donor Risk Index and European Eurotransplant
Donor Risk Index
Prospective GRI = dRI × rRI = expdonor factors × exprecipient factors
Prospective Global GRI = eg [(0.247 if > 50 donor age < 74) + (0.525 if donor age > 75) + (0.113 if DBD = CVA) + (0.122 if DBD = anoxia) + (0.365 if DBD = tumor )
+ (0.231 if DBD = other) + (0.174 if ABO = compatible) + (0.688 if ABO = incompatible) + (0.148 if ischemia 6-12 h) + (0.270 if ischemia > 12 h) + ( 0.285 if recipient
child) + (0.507 if recipient age > 60) + (0.329 if positive HCV recipient) + (0.322 if No. LT = 2) + (0.519 if No. LT > 3) + (0.140 if cirrhosis) + (0.285 if cancer) + (0.457 if
other, not cholestasis, neither fulminant, nor metabolic) + (0.457 if UNOS = 1) + (0.351 if UNOS = 2) + (0.077 if UNOS = 3) + (0.131 if extracorporeal bypass) + (
0.278 if piggyback)]
Prospective Early GRI = eg [(0.501 if DBD = tumor) + (0.300 if DBD = other) + (0.577 if ABO = incompatible) + (0.336 if ischemia 6-12 h) + (0.501 if ischemia > 12 h)
+ (0.329 if adult recipient age < 60) + (0.464 if No. OLT = 2) + (0.732 if No. OLT > 3) + (-0.446 if cirrhosis) + (-0.462 if cancer) + (1.015 if UNOS = 1) + (0.668 if UNOS
= 2) + (0.239 if UNOS = 3) + (0.215 if classic bypass) + (0.501 if extracorporeal bypass)]
Donor or Recipient Factor Reference Example Example 1 Example 2 Example 3 Example 4
D1 Age, y 35 64 78 80 82
D2 Cause DBD Trauma CVA CVA Anoxia Tumor
D3 ABO Isogroup Isogroup Isogroup Compatible Incompatible
D4 Ischemia, h < 6 < 6 6-12 > 12 > 12
R5 Age, y 45 55 62 64 64
R6 HCV No Yes Yes Yes Yes
R7 No. LT 1 1 1 3 3
R8 Disorder Cholestasis Cirrhosis Cirrhosis Cirrhosis Other
R9 UNOS 4 4 4 2 1
R10 Bypass Classic Piggyback Piggyback Piggyback Piggyback
Calculations
Global GRI 1 3.025 7.691 24.903 81.045
Early GRI 1 0.640 0.896 2.197 10.085
DRI (Feng et al5) 0.954 1.686 1.914 1.916 1.770
ET-DRI (Braat et al9) 0.956 1.651 1.865 1.866 1.730
Abbreviations: CVA: cerebrovascular accident; D, donor; DBD, donor brain dead; DCD, deceased cardiac donor; DRI, US Donor Risk Index; ET-DRI,
Eurotransplant Donor Risk Index; GRI, Graft Risk Index; HCV, hepatitis C virus; LT, liver transplant; OLT, orthotopic liver transplant; R, recipient; UNOS:
United Network for Organ Sharing
Underlined variables were included in the early GRI. Variables in italics were modified with respect to reference. For the calculation of the DRI and ET-DRI,
the variables not contemplated in the GRI have been considered of to have value 0 (risk 1).
Figure 1. Curve for the Predicted Event Probability for Early Graft Risk Index
With 95% Confidence Interval
Probability was observed for Graft Risk Index (GRI) < 3, ≤ 3 GRI < 5, ≤ 5
GRI < 7, and ≤ 7 GRI. Values are as follows: β0 = -3,650; β1 = 0,721; odds ratio
= e(β1) = 2057 (95% confidence interval, 1.571 – 2,963). Dots show observed
values and lines show predicted values.
In our comparison of indicators, no statistically
significant differences in mean DRI results were 
seen between groups with and without graft
survival. However, the GRI (global and early) results
showed significant differences between both groups
(Table 5).
Regarding early survival, risk group stratification
of the DRI and ET-DRI values did not show
significant differences in early graft survival 
between these indicators and global GRI, except 
for the group with extreme values. Only early 
GRI showed better survival discrimination, with 
an observation of a progressive decrease in survival
in which an early GRI value ≥ 3 indicated a
probability of graft survival at 1 month of 68.0% (95%
CI, 46.2-82.5) and a significant increase in risk
compared with the standard group (HR = 10.15, 
95% CI, 3.91-26.32; P < .001) (Table 6). With regard to
global survival, all indexes showed differences
between extreme groups, with GRI having the best
discrimination.
Our power of prediction calculation using
receiver operating characteristic area under the 
curve showed values of 0.52 (95% CI, 0.43-0.62) and 
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table 2. Main Characteristics of the Cohort
Variable Transplant Recipient
(N = 600)
Mean age ± SD, y 54.2 ± 9.7
Median age (interquartile range), y 55 (48-61)
Range, y 15-69
Male sex (% vs female) 447 (74.6)
Blood type, No. (%)
O 252 (41.9)
A 283 (47.2)
B 49 (8.2)
AB 16 (2.7)
Mean MELD score ± SD 16.2 ± 5.9
Child-Pugh class (N = 464), No. (%)
A 78 (16.8)
B 165 (35.6)
C 221 (47.6)
UNOS status, No. (%)
ICU admission 50 (8.3)
Hospital admission 102 (17.0)
With continuous care 277 (46.2)
At home 17 (28.5)
Cause of liver disease, No. (%)
Cholestasis 6 (1.0)
Metabolic 10 (1.7)
Cancer 16 (2.7)
Fulminant 20 (3.4)
Other 84 (14.0)
Retransplant 78
Cirrhosis 464 (77.3)
Alcohol 234 (39.0)
Virus 181 (30.2)
HBV 27 (4.5)
HCV 154 (25.7)
HCV + HBV coinfection 3
HCV + HIV coinfection 10
Cryptogenetic 22 (3.7)
Autoimmune 15 (2.5)
Biliary 12 (2.0)
Total cirrhosis with HCC 120
Mean time on wait list ± SD, mo 80.4 ± 103
Median wait time by blood type 
(interquartile range), mo
O 47 (13-122)
A 49 (11-112)
B 36 (9-109)
AB 26 (6-73)
table 3. Characteristics of Liver Transplant Donors
Variable Donor (N = 600)
Matching donor variables
Mean age ± SD, y 52.9 ± 17.8
Median age (interquartile range), y 56 (40-68)
Age range, y 11-87
Male sex (% vs female) 364 (60.7)
Mean days in ICU ± SD 2.9 ± 2.1
Cause of death, No. (%)
CVA 401 (66.8)
Trauma 144 (24.0)
Anoxia 41 (6.8)
Tumor 3 (0.5)
Others 11 (1.8)
Donor allocation, No. (%)
Local (same city) 415 (69.2)
Regional (within < 200 km) 22 (3.7)
National (> 200 km) 163 (27.1)
Hemodynamic, No. (%)
Noradrenaline 402 (67.0)
Cardiac arrest 82 (13.7)
Diabetes insipidus 189 (31.7)
Laboratory analysis, mean ± SD 
(interquartile range)
Sodium, mmol/L 147 ± 11 (138-194)
AST, IU/L 51 ± 73 (5-920)
ALT, IU/L 40 ± 52 (4-497)
GGT, IU/L 65.8 ± 78.1
HBcAb positive, No. (%) 49 (8.2)
CMV positive, No (%) 497 (82.8)
Steatosis
Mild 61 (10.2)
Moderate 3 (0.5)
Peritransplant variables
Elective (% vs urgent) 544 (90.7)
Correlation (donor vs recipient)
Blood type, No. (%)
Isogroup 576 (96.0)
Compatible 19 (3.2)
Incompatible 5 (0.8)
Same sex 343 (57.2)
Technique
UW preservation solution, No. (%) 362 (60.3)
Mean CIT ± SD, min 353 ± 114
Median CIT (interquartile range), min 330 (276-410)
CIT range, min 125-792
Mean surgery time ± SD, min 325 ± 64
Intraoperative event, No. (%)
Reperfusion injury 88 (14.7)
Intraoperative mortality 0
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HIV, human immunodeficiency virus; ICU, intensive care
unit; MELD, Model for End-Stage Liver Disease; SD, standard deviation;
UNOS, United Network for Organ Sharing
Abbreviations: ALT, alanine aminotransferase; AST, aspartate
aminotransferase; CIT, cold ischemia time; CMV, cytomegalovirus; GGT,
gamma glutamyl transpeptidase; HBcAb, hepatitis B virus core antibody;
ICU, intensive care unit; UW, University of Wisconsin 
0.54 (95% CI, 0.45-0.65) for DRI and ET-DRI,
respectively, indicating that their capacity to predict
graft survival was not better than chance. The
receiver operating characteristic area under the curve
analysis of global GRI was 0.68 (95% CI, 0.60-0.76)
and that of early GRI was 0.69 (95% CI, 0.61-0.77)
(Figure 2).
Discussion
Recently, benchmark16 indicators have been described
regarding outcomes after liver transplant, including
surgical outcomes, patient and graft survival, patient
care in the ICU, complications, length of stay, and
other factors.
Regarding length of stay in the ICU, Pedersen and
associates,17 in a study of factors associated with a
longer stay in the ICU, found that pretransplant
MELD was the most potent predictor of prolonged
ICU stay. Stratigopoulou and colleagues18 confirmed
that MELD and transplant duration are independent
predictors of prolonged ICU stay. However, Rana
and associates19 described a new index to predict 
the length of posttransplant hospitalization; of 22
independent risk factors associated with longer
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table 4. Liver Transplant Results
Variable Transplant Result  
(N = 600)
Primary non/dysfunction, No. (%) 7 (1.2)
Complication, No. (%)
Acute rejection 46 (7.7)
Vascular 21 (3.5)
Biliary 36 (6.0)
Mean days in ICU ± SD 7.9 ± 8.2
Mean hospitalization days ± SD 15.2 ± 11.9
Mean total days ± SD 23.0 ± 15.2
Retransplant, No. (%) 74 (12.3)
Retransplant reason, No. (%)
Primary non/dysfunction 5 (6.8)
Recurrence 14 (18.9)
Chronic rejection 18 (24.3)
Vascular complications 18 (24.3)
Biliary complications 13 (17.6)
Other 6 (8.1)
Kaplan-Meier graft survival, 
mean ± SD (95% CI), %
1 year 75.3 (71.6-78.6)
3 years 66.3 (62.2-70.1)
5 years 61.4 (57.1-65.4)
Mean follow-up ± SD, d 2280.4 ± 1978.9
Median follow-up (interquartile range), d 1880.5 (452-3715)
Follow-up range, d 1-6956
Global patient death 224* (37.3)
With functioning graft
DDG 104 (46.4)
DFG 120 (53.6)
Kaplan-Meier patient survival, 
mean ± SD (95% CI), %
At 1 year 80.7 (77.3-83.6)
At 3 years 72.9 (69.0-76.4)
At 5 years 68.3 (64.2-72.0)
table 5. US Donor Risk Index and European Eurotransplant Donor Risk Versus Graft Risk Index Values With and Without Retransplant or Death
Indicator No (n = 555) Yes (n = 45) P Value
DRI (Feng et al5) Mean and 95% CI 1.572 (1.541-1.604) 1.609 (1.474-1.743) .538
Median and interquartile range 1.555 (1.295-1.808) 1.642 (1.253-1.904)
ET-DRI (Braat et al9) Mean and 95% CI 1.552 (1.523-1.581) 1.607 (1.481-1.732) .314
Median and interquartile range 1.557 (1.278-1.774) 1.641 (1.284-1.917)
Range 0.935-2.541 0.950-2.355
Global GRI Mean and 95% CI 5.478 (5.180-5.776) 8.046 (6.516-9.576) < .001
Median and interquartile range 4.627 (3.238-6.681) 6.411 (4.527-9.531)
Range 1.478-38.283 2.477-24.829
Early GRI Mean and 95% CI 1.266 (1.205-1.326) 2.094 (1.631-2.556) < .001
Median and interquartile range 1.146 (0.640-1.603) 1.603 (1.109-2.590)
Range 0.630-5.207 0.640-7.360
Abbreviations: 95% CI, 95% confidence interval; DDG, died with
dysfunctional graft; DFG, died with functioning graft; ICU intensive care
unit; SD, standard deviation
*21 Patients died while on retransplant wait list.
Abbreviations: 95% CI, 95% confidence interval; DRI, US Donor Risk Index; ET-DRI, Eurotransplant Donor Risk Index; GRI, Graft Risk Index 
Figure 2. Receiver Operating Characteristic Curve Analysis
Abbreviations: DRI, US Donor Risk Index; ET-DRI, Eurotransplant Donor
Risk Index; GRI, Graft Risk Index; ROC, receiver operating characteristic
curve
hospital stay, the 2 most significant were shown 
to be previous admission of the recipient to the 
ICU (odds ratio of 1.75; 95% CI, 1.58-1.95) 
and previous transplant (odds ratio of 1.60; 95% CI,
1.47-1.75).
Regarding morbidity and mortality in the ICU,
preventing complications is a key factor in the
evolution of these patients and begins with
appropriate donor-recipient matching. Traditional
indicators used to assess the prognosis of cirrhosis
(Child-Pugh) or mortality on the liver transplant wait
list (MELD) are not valid to predict posttransplant
patient survival. Recent indicators based on neural
networks are complex, based on limited experience,
have low generalization capacity, and are difficult to
extrapolate to daily clinical practice. Finally, the
external validations of some indicators (DRI, MELD,
vs D-MELD; SOFT, DRI, vs ET-DRI; and DRI vs
SOFT)20 could not be confirmed when applied in
different scenarios from the one originally described,
such as in our study. The latter is likely because of
the large differences between countries and regions
regarding donor population characteristics and the
donation-transplant process and less to recipient
characteristics.
With regard to indicators, donor-related variables
may be associated with specific graft characteristics
and general characteristics of the “donor per se.”
Most described indicators share some common
variables, such as age and cause of brain death,
among others. However, some indicators are 
those whose use is not based on a solid scientific
basis, such as height. Although steatosis is a main
determinant of posttransplant liver function
(especially in the first year), as described by Kulik and
associates21 in a recent study, it is striking that 
it has not been included in any of the indicators
described.
Donor age has been included in many indicators.22
However, in RETH, it is an independent risk factor
regarding overall graft survival but not with respect
to short-term graft survival (< 1 mo), which has been
previously concurred by an international group23
and by our group.24,25
Risk factors include advanced age, and,
traditionally, donor hypernatremia has been as -
sociated with primary graft dysfunction or initial
poor graft function.26 Subsequent studies have not
confirmed these findings; however, donor hyper -
natremia may be associated with marginal livers, but
only alanine aminotransferase levels (> 65 IU/L)
were associated with a higher incidence of primary
graft dysfunction.27
Variables associated with the donor per se should
be included as indicators of graft survival. Some of
these variables have been grouped internationally
under the concept of expanded criteria donors. These
include drug abuse, tumors, infections, hepatitis B/C,
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table 6. Adjusted 1-Month and 1- to 5-Year Graft Survival and Hazard Ratio According to Index Stratification
Index Stratification Early (1 month) Global (1 and 5 years)
Index Cases Events Kaplan-Meier Cox Regression Events Kaplan-Meier, Kaplan-Meier, Cox Regression Global
(N = 600) (N = 45) Survival (N = 298) 1 year 5 years
No. % No. %* % 95% CI HR 95% CI P Value No. %* % 95% CI % 95% CI HR 95% CI P Value
DRI (Feng et al5)
DRI < 1.2 110 18.3 11 10.0 90.0 82.5-94.4 52 47.3 77.3 68.3-84.1 64.2 54.2-72.6
1.2 ≤ DRI < 1.6 210 35.0 11 5.2 94.8 90.9-97.1 0.50 0.22-1.16 NS 100 47.6 79.8 73.6-84.7 65.7 58.6-71.9 1.07 0.77-1.49 NS
1.6 ≤ DRI < 2 213 35.5 13 6.1 93.9 88.9-96.4 0.59 0.26-1.31 NS 103 48.4 75.4 68.9-80.7 61.7 54.2-68.3 1.29 0.92-1.81 NS
2 ≤ DRI 67 11.2 10 14.9 85.1 73.9-91.8 1.55 0.66-3.64 NS 43 64.2 58.0 45.1-68.9 42.4 30.0-54.3 2.09 1.39-3.14 < .001
Log-rank 0.0672 Log-rank 0.0008
ET-DRI (Braat et al9)
ET-DRI < 1.2 103 17.2 10 9.7 90.3 82.8-94.6 47 45.6 77.7 68.4-84.6 63.7 53.3-72.4
1.2 ≤ ET-DRI < 1.6 209 34.8 9 4.3 95.7 91.9-97.7 0.43 0.17-1.04 NS 96 45.9 80.2 74.0-85.1 67.5 60.6-73.5 1.07 0.75-1.52 NS
1.6 ≤ ET-DRI < 2 227 37.8 18 7.9 92.1 87.7-95.0 0.80 0.37-1.74 NS 116 51.1 75.1 68.9-80.3 59.0 51.8-65.5 1.46 1.04-2.06 < .05
2 ≤ ET-DRI 61 10.2 8 13.1 86.9 75.6-93.2 1.39 0.54-3.51 NS 39 63.9 55.7 42.3-67.1 42.9 31.0-56.1 2.11 1.37-3.23 < .001
Log-rank 0.0737 Log-rank 0.0005
Global GRI
1 ≤ GRI < 3 119 19.8 5 4.2 95.0 89.2-97.7 35 29.4 83.8 75.8-89.3 73.2 63.2 - 80.9
3 ≤ GRI < 5 240 40.0 10 4.2 96.2 93.0-98.0 0.74 0.26-2.07 NS 104 43.3 81.0 75.5-85.4 67.9 61.4 - 73.5 1.35 0.92-1.98 NS
5 ≤ GRI < 7 122 20.3 11 9.0 91.0 84.3-94.9 1.84 0.68-4.98 NS 70 57.4 72.1 63.1-79.2 55.9 46.6 - 64.2 1.77 1.17-2.65 < .01
7 ≤ GRI < 9 58 9.7 7 12.1 87.9 76.2-94.1 2.47 0.83-7.36 NS 36 62.1 70.5 56.9-80.5 54.4 40.2 - 66.6 2.06 1.29-3.29 < .01
9 ≤ GRI 61 10.2 12 19.7 80.3 67.9-88.3 4.14 1.55-11.0 .0045 53 86.9 47.5 34.6-59.3 32.8 21.5 - 44.6 4.03 2.63-6.19 < .001
Log-rank 0.0003 Log-rank 0.0003
Early GRI 
GRI < 1 241 40.2 9 3.7 96.3 93.0-98.0 92 38.2 81.0 75.3-85.5 67.4 60.5-73.4
1 ≤ GRI < 2 283 47.2 17 6.0 94.0 90.6-96.2 1.63 0.73-3.67 NS 152 53.7 77.3 71.9-81.8 62.5 56.5-67.9 1.17 0.89-1.52 .2505
2 ≤ GRI < 3 51 8.5 11 21.6 78.4 64.3-87.4 6.35 2.63-15.33 < .001 35 68.6 58.8 44.1-70.9 48.2 33.8-61.2 1.89 1.28-2.79 < .001
3 ≤ GRI 25 4.1 8 32.0 68.0 46.2-82.5 10.15 3.91-26.31 < .001 19 76.0 32.0 15.3-50.1 24.0 9.8-41.6 2.82 1.71-4.64 < .001
Log-rank < 0.0001 Log-rank < 0.0001
Abbreviations: 95% CI, 95% confidence interval; DRI, US Donor Risk Index; ET-DRI, Eurotransplant Donor Risk Index; GRI, Graft Risk Index; NS, not significant
*% Events in “n of subgroup.”
age > 65 years, and high transaminase/bilirubin
levels.
Regarding recipient-related variables, we have
already stated how the previous clinical condition of
the recipient could affect length of stay in the ICU
(these include high MELD score and United Network
for Organ Sharing status). Allocating an organ to the
most appropriate recipient is one of the most difficult
decisions. We agree with Feng and associates5 that an
ideal graft is homogeneous, allowing allocation of an
optimal organ to anyone; however, nonideal grafts
are heterogeneous, covering a wide spectrum of risk.
In the latter case, allocating a suboptimal organ to a
recipient with high MELD,28,29 specific conditions,30
or conditions with higher wait list mortality could
interfere with the risk of patient survival against wait
list mortality.31 Therefore, an indicator should
include this aspect in its design.
With regard to process-related variables, most
indicators have included cold ischemia time in their
design. Cold ischemia time may depend in turn on
donor location, available means of transportation,
surgical variables, and other factors. We believe a
good indicator should be known at the time of 
organ donation and should not include other added
variables (eg, donor location and cold ischemia 
time).
Another much debated issue is the influence of
the number of transplants performed at the center on
morbidity and mortality rates. Muller and associates16
analyzed this effect, concluding that centers with a
higher proportion of reference transplants had more
biliary complications. However, in our RETH
analyses, the number of transplants performed at the
center did not constitute an independent risk factor
for graft survival.
The present study has some limitations. Although
the indicator described is based on a national registry
of more than 22 000 transplants, it has been validated
with a limited series of a single center. These indexes
aim to predict and simplify complex situations
depending on many factors and, in many cases,
simplify quantitative variables (eg, time of cardiac
arrest, cold ischemia time) to categorical ones.
In the future, decision-making should be based on
complex artificial neural networks32 that will
eventually replace medical doctors. However, until
then, we will continue the search for tools that
decrease errors in our donor-recipient matching
decisions.
Conclusions
We found that neither DRI nor ET-DRI adequately
predicted graft risks in our setting. Therefore, it is
necessary to have an indicator to predict post -
transplant graft survival that is adapted to the
environment in which it will be used. A national GRI
can be a useful tool to optimize donor-recipient
matching. Therefore, a national study would allow
delineation of indicators and a more extensive
validation to be performed.
References
1. Bates E, Martin D. Immediate postoperative management and
complications on the intensive care unit. Br J Hosp Med (Lond).
2017;78(5):273-277.
2. Brown RS, Jr., Kumar KS, Russo MW, et al. Model for end-stage liver
disease and Child-Turcotte-Pugh score as predictors of
pretransplantation disease severity, posttransplantation outcome,
and resource utilization in United Network for Organ Sharing
status 2A patients. Liver Transpl. 2002;8(3):278-284.
3. Desai NM, Mange KC, Crawford MD, et al. Predicting outcome
after liver transplantation: utility of the model for end-stage liver
disease and a newly derived discrimination function.
Transplantation. 2004;77(1):99-106.
4. Ioannou GN. Development and validation of a model predicting
graft survival after liver transplantation. Liver Transpl. 2006;12(11):
1594-1606.
5. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics
associated with liver graft failure: the concept of a donor risk
index. Am J Transplant. 2006;6(4):783-790.
6. Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following
liver transplantation (SOFT) score: a novel method to predict
patient survival following liver transplantation. Am J Transplant.
2008;8(12):2537-2546.
7. Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-
MELD, a simple predictor of post liver transplant mortality for
optimization of donor/recipient matching. Am J Transplant.
2009;9(2):318-326.
8. Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better
guidelines for allocation in liver transplantation? A novel score
targeting justice and utility in the model for end-stage liver
disease era. Ann Surg. 2011;254(5):745-753; discussion 753.
9. Braat AE, Blok JJ, Putter H, et al. The Eurotransplant donor risk
index in liver transplantation: ET-DRI.Am J Transplant. 2012;12(10):
2789-2796.
10. Briceno J, Cruz-Ramirez M, Prieto M, et al. Use of artificial
intelligence as an innovative donor-recipient matching model for
liver transplantation: results from a multicenter Spanish study. J
Hepatol. 2014;61(5):1020-1028.
11. Lau L, Kankanige Y, Rubinstein B, et al. Machine-learning
algorithms predict graft failure after liver transplantation.
Transplantation. 2017;101(4):e125-e132.
12. Collett D, Friend PJ, Watson CJ. Factors associated with short- and
long-term liver graft survival in the United Kingdom:
Development of a UK donor liver index. Transplantation. 2017;
101(4):786-792.
13. Winter A, Feray C, Audureau E, et al. A donor quality index for liver
transplantation: development, internal and external validation.
Sci Rep. 2018;8(1):15109.
14. Araiz Burdio JJ, Serrano Aullo MT, Garcia Gil A, et al. Graft survival
after liver transplantation: an approach to a new Spanish risk
index. Rev Esp Enferm Dig. 2018;110(12):782-793.
15. Spanish Liver Transplant Registry. http://www.sethepatico.org.
7Juan José Araiz Burdio et al/Experimental and Clinical Transplantation (2019)
16. Muller X, Marcon F, Sapisochin G, et al. Defining benchmarks in
liver transplantation: a multicenter outcome analysis determining
best achievable results. Ann Surg. 2018;267(3):419-425.
17. Pedersen MR, Choi M, Brink JA, Seetharam AB. Pretransplant
factors and associations with postoperative respiratory failure, ICU
length of stay, and short-term survival after liver transplantation
in a high MELD population. J Transplant. 2016;2016:6787854.
18. Stratigopoulou P, Paul A, Hoyer DP, Kykalos S, Saner FH,
Sotiropoulos GC. High MELD score and extended operating time
predict prolonged initial ICU stay after liver transplantation and
influence the outcome. PLoS One. 2017;12(3):e0174173.
19. Rana A, Witte ED, Halazun KJ, et al. Liver transplant length of stay
(LOS) index: A novel predictive score for hospital length of stay
following liver transplantation. Clin Transplant. 2017;31(12).
20. Jadlowiec CC, Taner T. Liver transplantation: Current status and
challenges. World J Gastroenterol. 2016;22(18):4438-4445.
21. Kulik U, Lehner F, Klempnauer J, Borlak J. Primary non-function is
frequently associated with fatty liver allografts and high mortality
after re-transplantation. Liver Int. 2017;37(8):1219-1228.
22. Ghinolfi D, Marti J, De Simone P, et al. Use of octogenarian donors
for liver transplantation: a survival analysis. Am J Transplant.
2014;14(9):2062-2071.
23. Bertuzzo VR, Cescon M, Odaldi F, et al. Actual risk of using very
aged donors for unselected liver transplant candidates: a
European single-center experience in the MELD era. Ann Surg.
2017;265(2):388-396.
24. Franco CC, Martinez JM, Bellido CB, et al. Results of liver transplants
from donors aged 70 plus: analysis of Andalusian transplant
register. Transplant Proc. 2013;45(10):3647-3649.
25. Seller-Perez G, Herrera-Gutierrez ME, Lebron-Gallardo M, Moreno-
Quintana J, Banderas-Bravo E, Quesada-Garcia G. [Liver
transplantation: influence of donor-related factors]. Med Intensiva.
2008;32(8):378-384.
26. Gonzalez FX, Rimola A, Grande L, et al. Predictive factors of early
postoperative graft function in human liver transplantation.
Hepatology. 1994;20(3):565-573.
27. Sirivatanauksorn Y, Taweerutchana V, Limsrichamrern S, et al.
Analysis of donor risk factors associated with graft outcomes in
orthotopic liver transplantation. Transplant Proc. 2012;44(2):320-
323.
28. Grat M, Wronka KM, Patkowski W, et al. Effects of donor age and
cold ischemia on liver transplantation outcomes according to the
severity of recipient status. Dig Dis Sci. 2016;61(2):626-635.
29. Schlegel A, Linecker M, Kron P, et al. Risk assessment in high- and
low-MELD liver transplantation. Am J Transplant. 2017;17(4):1050-
1063.
30. Schoening W, Helbig M, Buescher N, et al. Eurotransplant donor-
risk-index and recipient factors: influence on long-term outcome
after liver transplantation - A large single-center experience. Clin
Transplant. 2016;30(5):508-517.
31. Araiz JJ, Serrano MT, Garcia-Gil FA, et al. Intention-to-treat survival
analysis of hepatitis C virus/human immunodeficiency virus
coinfected liver transplant: Is it the waiting list? Liver Transpl.
2016;22(9):1186-1196.
32. Ayllon MD, Ciria R, Cruz-Ramirez M, et al. Validation of artificial
neural networks as a methodology for donor-recipient matching
for liver transplantation. Liver Transpl. 2018;24(2):192-203.
8 Juan José Araiz Burdio et al/Experimental and Clinical Transplantation (2019) Exp Clin Transplant
